Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Terminated 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2Plasma cell 1Other hematologic neoplasm 1Myeloid 1Genitourinary 1Gastrointestinal 1Classical hematology 1Breast 1

Conditions

Neoplasms 13Carcinoma, Hepatocellular 7Carcinoma, Renal Cell 4Lymphoma 3Endometrial Neoplasms 3Squamous Cell Carcinoma of Head and Neck 2Lymphoma, Non-Hodgkin 2Liver Neoplasms 2Hodgkin Disease 2Carcinoma, Non-Small-Cell Lung 2Carcinoma 2Breast Neoplasms 2Urologic Neoplasms 1Triple Negative Breast Neoplasms 1Thrombocytosis 1Solid Tumor 1Rectal Neoplasms 1Prostatic Neoplasms 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Pancreatic Neoplasms 1Pancreatic Ductal Adenocarcinoma 1Ovarian Neoplasms 1Neoplasm Metastasis 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Myelodysplastic Syndromes 1Multiple Myeloma 1Melanoma 1

Interventions

Cyclophosphamide 58Rituximab 54fludarabine 33fludarabine phosphate 32venetoclax 24Filgrastim 22Etoposide 18Bendamustine Hydrochloride 18Gemcitabine 17Peripheral Blood Stem Cell Transplantation 15Bortezomib 15Melphalan 14obinutuzumab 13Lenalidomide 12Dexamethasone 12Cytarabine 12Vincristine 11Vorinostat 10Tacrolimus 10Azacitidine 10pembrolizumab 9Prednisone 9Mycophenolic Acid 9Doxorubicin 9ibrutinib 8copanlisib 8Whole-Body Irradiation 8Radiotherapy 8Paclitaxel 8Interleukin-2 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Lymphoma, Non-Hodgkin × lenvatinib × Clear all
NCT03878524 2024-03-04

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

OHSU Knight Cancer Institute

Phase 1 Terminated
2 enrolled
BreastClassical hematologyGastrointestinalGenitourinaryLymphoidMyeloidOther hematologic neoplasmPlasma cell

Anemia, Blast Crisis, Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasm Metastasis, Pancreatic Neoplasms, Prostatic Neoplasms, Thrombocytosis, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

NCT00121719 2023-06-22

An Open Label Dose Escalation Study Of E7080

Eisai Inc.

Phase 1 Completed
82 enrolled 34 charts
Lymphoid

Hodgkin Disease, Lymphoma, Lymphoma, Non-Hodgkin, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡